Skip to main content
Home
FDA
  • LOG IN
  • Thompson FDA
  • Manage Account
  •  
  • 1.800.677.3789

Main navigation

  • LIBRARY
    • FDA Enforcement Manual
    • Guide to Good Clinical Practice
    • FDA Advertising and Promotion Manual
    • Guide to Medical Device Regulation
    • Guide to U.S. Food Labeling Law
  • MY RESEARCH
  • NEWS
    • All News
    • FDA Intelligence
  • DATABASES
    • FDA Enforcement Database
    • Clinlaw State Database
  • RESOURCES
    • FDA Forms
    • Special Reports
    • Judicial Opinions
    • Interactive Tools
  • AGENCY GUIDANCE
    • Enforcement Guidance
    • Clinical Trials Guidance
    • Advertising and Promotion Guidance
    • Medical Device Guidance
    • Food Labeling Guidance
  • ASK THE EXPERT

Login to the Thompson
FDA Compliance Expert

Enter your FDA username.
Enter the password that accompanies your username.
Forgot password?

Questions? Give us a call! 1-800-677-3789

Advertising & Promotion

  • Apr 1, 2026
    DTC TV Ad, Podcast Misrepresent Indications for Bladder Cancer Drug, OPDP Alleges in Warning Letter
  • Mar 26, 2026
    Maryland Legislation Would Impose Registration, Disclosure Mandates for Disease Awareness Campaigns
  • Mar 13, 2026
    FDA Warns Novo Nordisk, Telehealth Companies About GLP-1 Ads
  • Mar 6, 2026
    Bayer Sues J&J Alleging False Advertising of Erleada
  • Feb 27, 2026
    Clinical Investigator Receives Warning Letter Over Incorrect Dosing
  • Feb 27, 2026
    CVM Issues First Promotion Warning Letter of 2026
  • Feb 20, 2026
    Florida Bills Would Allow Individuals To Sue Over Vaccine Harm, If Products Are Advertised in the State
  • Feb 13, 2026
    OPDP Sends Five Untitled Letters Over DTC TV Ads
  • Jan 30, 2026
    FDA Sends Second Untitled Letter Over Nasal Spray’s DTC Ad
  • Jan 26, 2026
    Oklahoma Bill Would Ban DTC Prescription Drug Ads
  • More

Good Clinical Practice

  • Mar 31, 2026
    FDA Seeks Input on Digital Health Technologies for Use in Clinical Trials for Drugs, Biologics
  • Mar 13, 2026
    CBER Sends Untitled Letter Over Adverse Event Reporting
  • Feb 27, 2026
    Clinical Investigator Receives Warning Letter Over Incorrect Dosing
  • Feb 20, 2026
    Senate HELP Committee Chair Calls for FDA Reforms Affecting Trials
  • Feb 9, 2026
    Research Center Receives Warning Letter Over Failure To Submit IND for Trial
  • Feb 1, 2026
    National Academies Report Finds NIH Needs Culture of Ethical Inclusion of Children in Research
  • Jan 16, 2026
    FDA Sends Warning Letters a Year After BIMO Inspections
  • Jan 13, 2026
    Draft Guidance on Bayesian Analysis Aims for More Efficient Trials
  • Jan 3, 2026
    Two Clinical Investigators Receive Warning Letters
  • Dec 27, 2025
    FDA Releases Three Year-End Trial Guidances
  • More

U.S. Food Labeling

  • Mar 6,2026
    FDA Examines Food Allergen Thresholds
  • Mar 4,2026
    Court Won’t Halt Suit Alleging Amazon Supplement Labeling Violations While FDA Ponders Reg Change
  • Feb 25,2026
    District Court Issues Injunction Against Texas Warning Label Law
  • Feb 13,2026
    FDA Will Allow ‘No Artificial Colors’ Labels for Products Not Using Oil-Based Dyes
  • Feb 7,2026
    Human Foods Program Releases Priorities for 2026
  • Jan 30,2026
    States Legislatures Ponder Food Labeling Bills
  • Jan 23,2026
    FDA Opens Request for Information on Gluten Labeling
  • Jan 21,2026
    U.S. Appeals Court Affirms Certification in Class Action Suit Alleging Deceptive Labeling
  • Jan 7,2026
    Food Trade Groups Sue Texas Over Warning Label Law
  • Jan 2,2026
    Bipartisan House Bill Would Require FOP Health Warnings
  • More

FDA Regulation & Enforcement

  • Apr 1, 2026
    Eli Lilly Urges Supreme Court To Examine Constitutionality of False Claims Act’s Whistleblower Provisions
  • Apr 1, 2026
    DTC TV Ad, Podcast Misrepresent Indications for Bladder Cancer Drug, OPDP Alleges in Warning Letter
  • Mar 26, 2026
    Maryland Legislation Would Impose Registration, Disclosure Mandates for Disease Awareness Campaigns
  • Mar 25, 2026
    Supreme Court Won’t Hear Appeal of Medtech Exec Convicted for COVID-19, Allergy Testing Schemes
  • Mar 19, 2026
    DOJ Develops First-Ever Uniform Corporate Criminal Enforcement Policy, Urges Self-Disclosure
  • Mar 13, 2026
    FDA Warns Novo Nordisk, Telehealth Companies About GLP-1 Ads
  • Mar 11, 2026
    In Releasing Draft Guidance, FDA Seeks To Improve Form 483 Responses Following Drug cGMP Inspections
  • Mar 11, 2026
    Regulatory Executive To Plead Guilty to Hiding Adverse Events, Including Patient Deaths, From FDA
  • Mar 6, 2026
    FDA Examines Food Allergen Thresholds
  • Mar 6, 2026
    Bayer Sues J&J Alleging False Advertising of Erleada
  • More

Medical Devices

  • Apr 1, 2026
    Final Guidance Describes Roles of Patient Preference Information in Submissions, FDA Decision-Making
  • Mar 25, 2026
    AI-Enhanced Medical Technology Specifically Indicated for Pediatric Use Remains Scarce, Researchers Find
  • Mar 18, 2026
    Guidance on Weight Loss Devices Specifies Risk-Benefit Factors Considered by FDA Reviewers
  • Mar 11, 2026
    Regulatory Executive To Plead Guilty to Hiding Adverse Events, Including Patient Deaths, From FDA
  • Mar 5, 2026
    Preemption, Inadequate Pleading Doom Patient’s Tort Suit Against Pain Management Device Manufacturer
  • Feb 25, 2026
    AdvaMed Seeks Certainty, Stability in U.S. Tariff Policy Following Supreme Court Decision
  • Feb 25, 2026
    Device Maker’s Non-Prosecution Agreement Resolves Allegations of Health Care, Securities Fraud
  • Feb 11, 2026
    Revised Device Cybersecurity Guidance Explores Impact of Quality Management System Regulation
  • Feb 4, 2026
    Enviro Groups Ask Court To Invalidate Trump EtO Emissions Control Exemptions for Device Sterilizers
  • Feb 4, 2026
    Quality Management System Device Inspections Will Focus on Risk Under New Compliance Program
  • More

THOMPSON FDA

  • Thompson FDA
  • About Us
  • Manage Account
  • Our Parent Company

COMPLIANCE EXPERT

  • News
  • My Research
  • Our Experts
  •  

RESOURCES

  • FDA Forms
  • Special Reports

HELP

  • Customer Support
  •  
  •  
  •  
  •  

CONTACT

  • headquarter Headquarters
  • contact-number 1.800.677.3789
  • Contact Us
  •  

Copyright © Thompson FDA, a division of CBIS. All rights reserved.

  • Terms
  • Privacy

FDA NEWS
YOU CAN USE

Get instant, free access to the latest news and analysis to keep up with the shifting requirements, recommendations, and expectations of the FDA.

Something went wrong. Please try after some time.